Celldex Therapeutics (CLDX) Set to Announce Earnings on Wednesday

Celldex Therapeutics (NASDAQ:CLDX) is scheduled to post its quarterly earnings results after the market closes on Wednesday, August 7th. Analysts expect Celldex Therapeutics to post earnings of ($1.17) per share for the quarter.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.14) by $0.01. Celldex Therapeutics had a negative net margin of 729.59% and a negative return on equity of 45.09%. The business had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.26 million. On average, analysts expect Celldex Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of NASDAQ CLDX opened at $2.16 on Friday. The company has a quick ratio of 7.41, a current ratio of 7.41 and a debt-to-equity ratio of 0.02. Celldex Therapeutics has a 12 month low of $2.03 and a 12 month high of $11.63. The company has a market cap of $29.19 million, a price-to-earnings ratio of -0.32 and a beta of 3.67. The stock has a fifty day moving average of $2.51.

Several research analysts have commented on the stock. HC Wainwright set a $19.00 price objective on shares of Celldex Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 8th. Zacks Investment Research raised shares of Celldex Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 24th. Finally, ValuEngine downgraded shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $12.38.

About Celldex Therapeutics

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Featured Story: How to build a Fibonacci channel

Earnings History for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.